INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Sep 17, 2003 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 24,636 | $20.95 | 130,651 |
| Nov 01, 2018 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Bona fide gift | 24,643 | -- | -- |
| Dec 11, 2023 |
Director, Bd. Co-Chair, President & CSO
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,155 | -- | 765,327 |
| Dec 11, 2023 |
Director, Bd. Co-Chair, President & CSO
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,155 | -- | -- |
| Dec 11, 2019 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,155 | -- | 25,155 |
| Dec 16, 2008 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 26,991 | $7.41 | 590,085 |
| Dec 16, 2008 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 26,991 | $16.40 | 563,094 |
| Dec 16, 2008 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 26,991 | -- | -- |
| Jan 05, 2012 |
Director, EVP, CSO & Pres, REGN Res Labs
|
Director, EVP, CSO & Pres, REGN Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 27,713 | $58.00 | 833,041 |
| Feb 12, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 30,858 | $319.44 | 1,106,334 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.